Nektar Therapeutics（NKTR）株式概要
ネクター・セラピューティクス社はバイオ医薬品会社で、米国内外の免疫療法分野における医薬品の発見と開発に注力している。 詳細
NKTR Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.1% 割安 内在価値ディスカウント
5022.2%Revenue growth p.a.
3.7k
22
2
54
Nektar Therapeutics 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$85.04 |
| 52週高値 | US$109.00 |
| 52週安値 | US$7.99 |
| ベータ | 1.18 |
| 1ヶ月の変化 | 18.19% |
| 3ヶ月変化 | 127.81% |
| 1年変化 | 626.74% |
| 3年間の変化 | 615.55% |
| 5年間の変化 | -69.39% |
| IPOからの変化 | 51.18% |
最新ニュース
Recent updates
NKTR: Future Phase 3 Atopic Dermatitis Data Will Drive Upside Repricing Potential
Analysts have lifted the base case fair value estimate for Nektar Therapeutics from $135 to $165, citing recent Street research that highlights rezpeg data in atopic dermatitis and alopecia, a Phase 3 plan in atopic dermatitis, and a series of higher price targets and upgrades across multiple firms. Analyst Commentary Recent Street research on Nektar Therapeutics has tilted clearly positive, with several firms lifting price targets and highlighting rezpegaldesleukin, or rezpeg, as the key driver for their valuation work.Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
Apr 15
NKTR: Phase 3 Atopic Dermatitis Program And Data Strength Will Drive Future Upside
The analyst price target for Nektar Therapeutics has been adjusted from $136.43 to $128.13 as analysts factor in updated rezpegaldesleukin Phase 2 data, plans for a Phase 3 atopic dermatitis study, and recent Street research that refines expectations around future sales potential and valuation multiples. Analyst Commentary Recent Street research around Nektar Therapeutics clusters around rezpegaldesleukin, with analysts updating models on the back of Phase 2 atopic dermatitis data, longer term maintenance results and the planned Phase 3 program.NKTR: Phase 3 Atopic Dermatitis Program Will Drive Future Upside Potential
The analyst fair value estimate for Nektar Therapeutics has shifted from $129.86 to $136.43, as analysts factor in higher modeled sales potential for rezpegaldesleukin in atopic dermatitis and alopecia, along with recent price target increases across several firms tied to progressing Phase 2 data and planned Phase 3 programs. Analyst Commentary Recent Street research around Nektar Therapeutics has focused on rezpegaldesleukin, with pricing models and risk assessments concentrating on its potential role in atopic dermatitis and alopecia as Phase 2 data matures and Phase 3 plans move forward.NKTR: Rezpeg Durability In Atopic Dermatitis And Alopecia Will Drive Future Upside
Analysts have lifted their price targets on Nektar Therapeutics, with one moving from $105 to $150, citing stronger conviction in Rezpeg's durability data in Atopic Dermatitis and alopecia areata, a clearer financing profile, and a more supportive catalyst path that is reflected in a higher fair value estimate of about $130 per share. Analyst Commentary Bullish Takeaways Bullish analysts point to the 52 week maintenance data from the REZOLVE AD study as reinforcing confidence in Rezpeg's durability, which they see as a key input to their higher fair value estimates.NKTR: Alopecia Areata Phase 2b Durability Will Drive Future Upside
Analysts have lifted their price target for Nektar Therapeutics by about $9, citing updated views on Rezpeg's durability, deepening clinical responses, and revised fair value assumptions as the key drivers of the change. Analyst Commentary Recent research updates show a cluster of upbeat views on Nektar Therapeutics, centered on Rezpeg's clinical profile and its potential role in Alopecia Areata and other indications.Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up
Feb 12
NKTR: Future Alopecia Areata Data Will Drive Upside Repricing Potential
Analysts have raised their fair value estimate for Nektar Therapeutics to $135 from $120, citing revised revenue growth assumptions, a lower future P/E multiple of about 165, and additional upside potential from Rezpeg in Alopecia Areata, which has an estimated $300 million in possible peak sales. Analyst Commentary Recent Street research has leaned positive on Nektar Therapeutics, with bullish analysts pointing to Rezpeg in Alopecia Areata as a key upside driver supporting higher valuation assumptions.NKTR: Alopecia Areata Phase 2b Data And Fast Track Will Drive Upside
Analysts have lifted their price target on Nektar Therapeutics from US$99 to US$121, citing Rezpeg's Phase 2b Alopecia Areata opportunity, its safety profile, durability potential, and an added 20% probability of success with about US$300m in estimated peak sales. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$121 price target as a reflection of added confidence in Rezpeg's Alopecia Areata opportunity and its potential to contribute meaningfully to Nektar's valuation over time.NKTR: Phase 2b Alopecia Data And Fast Track Status Will Drive Upside
Analysts have increased their price target for Nektar Therapeutics to $121 from $99, citing updated assumptions around Rezpeg, including new Alopecia Areata Phase 2b expectations, a clean safety profile, durability potential, and added value for future sales. They also highlighted the ongoing impact of Rezpeg related clinical data on how investors frame the separate Lilly litigation.More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25%
Dec 25NKTR: Upcoming Phase 2b Data Will Drive Upside Despite Litigation Uncertainty
Analysts have lifted their blended fair value estimate for Nektar Therapeutics from approximately $107 to $114 per share. They cite higher price targets driven by growing confidence in Rezpeg's Phase 2 data, its novel mechanism and safety profile, and incremental modeled peak sales, despite slightly more conservative long term revenue growth assumptions.NKTR: Late-Stage Clinical Data Will Drive Upside Despite Litigation Delays
Analysts have raised their price target for Nektar Therapeutics from approximately $94 to $107 per share. They cite growing confidence in the commercial potential of Rezpeg following recent positive clinical data and reinforced differentiation from competitors.NKTR: Positive Phase 2b Data Will Drive Momentum Amid Delayed Litigation
Analysts have raised their price target for Nektar Therapeutics from $69 to $99 per share. They cite recent positive clinical data and a stronger outlook for Rezpeg's competitive position in atopic dermatitis as the reasons for this adjustment.NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Analysts have raised their price target for Nektar Therapeutics to $99, up from $69. This change is attributed to positive Phase 2b study results for rezpegaldesleukin and increased confidence in its commercial potential.Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics' analyst price target has been revised downward from $101.17 to $93.86 per share. Analysts cite recent clinical updates and ongoing litigation developments as key factors influencing their outlook.Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics’ consensus price target has increased to $101.17, driven by positive Phase 2b REZOLVE-AD results for rezpegaldesleukin, which demonstrated robust efficacy and safety in atopic dermatitis, supporting increased conviction in its differentiated clinical and commercial profile. Analyst Commentary Bullish analysts are raising price targets following positive Phase 2b REZOLVE-AD data for rezpegaldesleukin, with all primary and secondary endpoints met and robust efficacy and safety demonstrated in moderate-to-severe atopic dermatitis.Nektar Therapeutics' (NASDAQ:NKTR) 28% Share Price Surge Not Quite Adding Up
Aug 28Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth
Jun 11Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be
May 15Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding
Apr 04
Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects
Fast-track designation and strategic partnerships could expedite REZPEG's market entry, enhancing near-term revenue and profit margins.Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop
Feb 10Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge
Dec 06Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking
Oct 18Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding
Jun 19株主還元
| NKTR | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | -6.8% | 0.3% | 0.6% |
| 1Y | 626.7% | 29.1% | 28.7% |
業界別リターン: NKTR過去 1 年間で16 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: NKTR過去 1 年間で27.6 % の収益を上げたUS市場を上回りました。
価格変動
| NKTR volatility | |
|---|---|
| NKTR Average Weekly Movement | 17.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
安定した株価: NKTRの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: NKTRの 週次ボラティリティ は過去 1 年間で27%から18%に減少しましたが、依然としてUS株の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1990 | 63 | Howard Robin | www.nektar.com |
ネクター・セラピューティクス社はバイオ医薬品会社で、米国内外の免疫療法分野における医薬品の発見と開発に注力している。自己免疫疾患や炎症性疾患の患者における根本的な免疫系の不均衡を治療するためフェーズ2b段階にあるrezpegaldesleukin、潰瘍性大腸炎、白斑、多発性硬化症を治療するNKTR-0165、自己免疫疾患を治療するNKTR-0166、線維性疾患を治療するNKTR-422、固形癌や大細胞型b細胞リンパ腫を治療するNKTR-255を開発している。武田薬品工業、アストラゼネカ、UCBファーマ、F.ホフマン・ラ・ロシュ、ボシュ・ヘルス・カンパニーズ、ファイザー、UCBファーマ（バイオジェン）、ブリストル・マイヤーズ スクイブ、メルクKGaAと提携契約を結んでいる。同社は1990年に設立され、カリフォルニア州サンフランシスコに本社を置いている。
Nektar Therapeutics 基礎のまとめ
| NKTR 基礎統計学 | |
|---|---|
| 時価総額 | US$2.81b |
| 収益（TTM） | -US$164.08m |
| 売上高(TTM) | US$55.23m |
52.0x
P/Sレシオ-17.5x
PER（株価収益率NKTR は割高か？
公正価値と評価分析を参照収益と収入
| NKTR 損益計算書（TTM） | |
|---|---|
| 収益 | US$55.23m |
| 売上原価 | US$0 |
| 売上総利益 | US$55.23m |
| その他の費用 | US$219.31m |
| 収益 | -US$164.08m |
直近の収益報告
Dec 31, 2025
次回決算日
May 07, 2026
| 一株当たり利益（EPS） | -4.86 |
| グロス・マージン | 100.00% |
| 純利益率 | -297.07% |
| 有利子負債／自己資本比率 | 70.3% |
NKTR の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/04/30 03:46 |
| 終値 | 2026/04/30 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Nektar Therapeutics 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31
| アナリスト | 機関 |
|---|---|
| Richard Silver | Barclays |
| Aydin Huseynov | Benchmark Company |
| George Farmer | BMO Capital Markets Equity Research |